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LETTER TO THE EDITOR
Response to ‘pervasive sequence patents cover
the entire human genome’
Shine Tu1*, Christopher Holman2, Adam Mossoff3, Ted Sichelman4, Michael Risch5, Jorge L Conteras6, Yaniv Heled7,
Greg Dolin8 and Lee Petherbridge9
See related Correspondence by Rosenfeld and Mason, http://genomemedicine.com/content/5/3/27 and related letter by Rosenfeld and Mason,
http://genomemedicine.com/content/6/2/15
Abstract
A response to Pervasive sequence patents cover the
entire human genome by J Rosenfeld and C Mason.
Genome Med 2013, 5:27.
Letter to the editor
In the article by Jeffrey Rosenfeld and Christopher Mason
published in Genome Medicine [1], significant misstate-
ments were made, because the authors did not sufficiently
review the claims - which define the legal scope of a patent
- in the patents they analyzed. The authors contend that
‘41% of the genes in the human genome have been claimed’
in US patents. Additionally, they suggest that claims to
shorter sequences, specifically 15mers, in a patent held by
Myriad Genetics (a litigant in the recent Supreme Court
case involving the patentability of genes [2]) cover 91.5% of
human genes. Their article has received wide attention in
the press and industry (for example, in CNBC [3], Fox
News [4] and CBS News [5]), and formed the basis for
opinion articles by the authors in the Washington Post [6]
and the Huffington Post [7].
We do not question the authors’ assertion [1] that as
k-mers become shorter, the likelihood that those k-mers
appear in some gene increases substantially. However, the
article does not accurately reflect the law behind gene
patenting, because by failing to specifically analyze the
claims of these patents, it overestimates the share of the
human genome that is ‘covered’ by US patents. As an initial
matter, unlike most articles in Genome Medicine, Rosenfeld
and Mason’s article [1] purports to make legal - rather than
purely scientific - assertions. Our criticisms do not depend
* Correspondence: shine.tu@mail.wvu.edu
1West Virginia University College of Law, PO Box 6130, Morgantown, WV
26506, USA
Full list of author information is available at the end of the article
on our viewpoint as patent lawyers or as patent law profes-
sors. As we describe below, the authors [1] make important
legal assertions that are either misleading or simply
incorrect.
More specifically, Rosenfeld and Mason [1] did not apply
the legal standards required for patent infringement and, in
turn, misinterpreted the scope of the CAMBIA patent
sequence database [8] when performing their analysis. In
order to arrive at a legitimate conclusion as to what subject
matter is ‘covered’ by a patent claim, it is absolutely neces-
sary to read and interpret every single limitation or element
in the patent claim. The patent claim defines the patented
invention, and infringement can occur only when every
element of a claim is met by the accused product or
process. Rosenfeld and Mason [1] identified patents that
mention DNA sequences, but then fail to review the other
terms and limitations required by the claims. Based on our
review of some of these claims, they almost all included
additional limitations and some simply mention the gene
sequence without even making the sequence a limitation in
the first place. For example, one patent they identify as
‘covering’ DNA sequences corresponding to human genes
also requires testing on a bovine subject. But they ignore
the required step of bovine testing when analyzing whether
their claim covers gene sequences. In fact, because this
claim requires testing, it is not a ‘composition of matter’
claim at all and cannot independently cover gene sequences.
The article by Rosenfeld and Mason [1] made an
assumption that just because a patent mentions a gene
sequence in a patent claim, any use or research of this
gene would result in patent infringement. This is not the
case. To directly infringe a claim that is directed to a
composition of matter (such as DNA) that comprises
elements 1, 2 and 3, one needs to make a composition
that includes at least elements 1, 2 and 3. If only element
1 is present, then there is no direct infringement of the
© 2014 BioMed Central Ltd.
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patent. For example, if a patent claims a bicycle with
handlebars, wheels and gears, one would not directly
infringe this patent by making only the handlebars.
For example, the authors [1] state that ‘15mer patent
claims from one gene will always ’cross-match‘ and
patent a portion of another gene as well.’ From a legal
standpoint, this statement is true only if the patent claim
is directed only to the 15mer itself. However, as one of
us (CH) has shown in his previous research, this is a rare
occurrence - in fact, the only 15mer patent that he was
able to find from searching hundreds of patents was the
Myriad 5,747,282 patent (‘the ‘282 patent’) [9]. The
authors’ [1] analysis assumes that simply because a
patent claim contains one limitation reciting a short
nucleotide sequence, such as a 15mer, it is effectively the
same as the 15mer claim in Myriad’s ’282 patent. We
agree that if hypothetical 15mer (or shorter) human
DNA composition of matter claims were routinely
granted, this would be extremely problematic because
they might cover a large percentage of genes. Such an
assertion has been made before, and is not terribly con-
troversial [10,11]. However, it is of little import, because
there are few (perhaps one) patent that does so, and any
such patent claim (such as the one in the ’282 patent)
would surely be invalid for lack of novelty.
Similarly, Rosenfeld and Mason [1] state that ‘we
found 58 patents whose claims covered at least 10% of
the bases of all human genes.’ One of us (ST) has
reviewed these 58 patents, and this is simply not the
case. The claims of most of these patents contain many
additional elements, and the fact that the claims contain
reference to human genes does not mean that using
nucleic acids directed to these sequences will necessarily
result in patent infringement (Additional file 1: Table
S1). As we stated earlier, it is essential to review every
claim limitation to determine what a claim covers and
what it does not.
Additionally, we note that some of the documents
listed under the 58 ‘patents’ examined by the authors [1]
of the Pervasive sequence article are actually ‘statutory
invention registrations’ (SIRs). SIRs are not patents and
do not give the holder any exclusive rights; they are used
purely as a defensive publication. In fact, SIRs require
the registrant to affirmatively waive any right to receive
a patent on the disclosed subject matter [12].
Rosenfeld and Mason [1] used the CAMBIA patent
database [8], which simply identifies DNA sequences if
they are mentioned anywhere in a patent claim. Yet, con-
trary to Rosenfeld and Mason’s findings [1], the CAMBIA
database fails to identify whether a DNA sequence that
happens to be mentioned in a claim is standing alone
encompassed - as a legal matter - under that patent claim.
As noted above, additional elements may be required by
the claim for a finding of infringement.
A manual review of patent claims to determine whether
DNA sequences mentioned within the claims are in fact
within the scope of the claims is more than feasible. First,
one would only need to review the 3,945 patents that were
matched from the CCDS gene sequence database [13] and
the CAMBIA patent database [8] (not tens of thousands
of patent claims). In fact, Graff et al. [14] show that there
are only 11,868 gene patents, with 5,936 patents directed
to humans. Second, one would only need to focus on the
claims (usually only one to three pages at the end of a
patent), and not necessarily read the entire patent. Finally,
one could limit the analysis to only composition of matter
claims. To do this quick first pass type of review, it took
one of us (ST) less than 1 hour to review approximately
60 patents. Accordingly, for 3,000 to 4,000 patents,
roughly 60 hours of work would be required - far under
the amount of time spent preparing a typical article
appearing in this journal. Interestingly, in a recent article,
Jefferson et al. [15] describe tools for the CAMBIA data-
base that begin to address this very issue.
We realize that Rosenfeld and Mason [1] are not
patent lawyers. The field of patent law is one that can be
both confusing and complex. However, we do not believe
that readers could plausibly interpret the Rosenfeld and
Mason [1] article as only making a statistical argument
about coverage and not legal interpretations about patent
law. Indeed, Rosenfeld and Mason [1] rely on their results
to propose that ‘the Supreme Court and Congress should
limit the patenting of existing nucleotide sequences
because of their broad scope and non-specificity in the
human genome.’
We note that none of the above necessarily reflects on
the position of the authors [1] in the ongoing debate
regarding the patentability of ‘gene patents’. Rather, we all
believe that this vital debate should be tethered to legal
reality. Also, since the publication of Rosenfeld and Mason
[1], the US Supreme Court has issued an opinion regard-
ing gene patents [2]. Specifically, the Court has drawn a
line between isolated DNA (not patentable subject matter)
and cDNA (patentable subject matter). According to the
Court, ‘[the patentee] did not create or alter either the
genetic information encoded [in the genes] or the genetic
structure of the DNA. [The patentee] found an important
and useful gene, but groundbreaking, innovative, or even
brilliant discovery does not by itself satisfy the [statutory
patentable subject matter requirement].’ However, the
Court also ruled that cDNA is not a ‘product of nature’,
and is thus patent-eligible [2].
It is well within our expertise as patent law professors
to rebut such arguments. Additionally, we have the ex-
pertise to understand the science, as all but two of us
have first degrees in biology or medicine and four of us
have PhDs in biological subjects or MDs. Put simply,
Rosenfeld and Mason [1] use their scientific results to
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make a legal argument, and that legal argument is based
on an incorrect view of the law. So it is to these legal
conclusions, and not their scientific results, that we
object. Specifically, the claims of the patent define the
legal boundaries and the inventor’s exclusionary rights.
Accordingly, it is legally insignificant that the short
nucleotide sequences statistically can be found in much
of the human genome, unless many patent claims solely
cover these short nucleotide sequences. Rosenfeld and
Mason [1] have shown nothing of the sort, and our initial
review of their patents indicates entirely otherwise.
Additional file
Additional file 1: Table S1. A brief analysis of the 58 patents
referenced in Additional file 2 of the Rosenfeld and Mason article [1].
Analysis only includes review of the independent claims of the patent,
and also a brief description of the elements necessary for patent
infringement are given.
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